Select Your Region

We noticed you visit this page from United States. Please select your preferred region to continue

skip to content

Country Selector

Based on your location

Europe

North America

Latin America

Asia-Pacific

Healthcare Professional Verification

This section contains medical information for licensed healthcare professionals only. Please confirm your professional status to continue.

The importance of testing anti-dsDNA, anti-nucleosome and anti-C1q antibodies in patients with systemic lupus erythematosus

Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease characterized by multisystem clinical presentation and serologic findings of various antibodies.

Publié: 11/29/2024 | Modifié: 8/6/2026
  • Anti-dsDNA and anti-nucleosome have high specificity and positive predictive value for Systemic lupus erythematosus (SLE) diagnosis
  • Anti-nucleosome and anti-C1q antibodies show an association with SLE and lupus nephritis activity, suggesting their potential usefulness in making predictions about lupus nephritis and assessment of disease activity
Anti-dsDNA_Publication

Tests associated with this resource

  • Anti-C1q

    • Connective Tissue Diseases
    • SMC Technology
    • ELISA
  • Anti-dsDNA

    • Connective Tissue Diseases
    • SMC Technology
    • ELISA

Related instruments

This section contains information intended for wide distribution and may therefore contain product details or information that is not available or valid in your country. Please contact your local Sebia representative. Information intended for healthcare professionals. Carefully read the instructions in the reagent package inserts and instrument manuals.

Anti-dsDNA, Anti-Nucleosome & Anti-C1q Antibodies in SLE Diagnosis | Sebia